GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance

Ott OJ, Strnad V, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Luis Guinot J, Dunst J, Gutierrez Miguelez C, Slampa P, Allgaeuer M, Lossl K, Polat B, Kovacs G, Fischedick AR, Wendt TG, Fietkau R, Kortmann RD, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Potter R, Gall C, Malzer M, Uter W, Polgar C (2016)

Publication Type: Journal article

Publication year: 2016

Journal

Book Volume: 120

Pages Range: 119-23

Journal Issue: 1

DOI: 10.1016/j.radonc.2016.06.019

Abstract

To compare early side effects and patient compliance of accelerated partial breast irradiation (APBI) with multicatheter brachytherapy to external beam whole breast irradiation (WBI) in a low-risk group of patients with breast cancer.Between April 2004 and July 2009, 1328 patients with UICC stage 0-IIA breast cancer were randomized to receive WBI with 50Gy and a boost of 10Gy or APBI with either 32.0Gy/8 fractions, or 30.1Gy/7 fractions (HDR-brachytherapy), or 50Gy/0.60-0.80Gy per pulse (PDR-brachytherapy). This report focuses on early side-effects and patient compliance observed in 1186 analyzable patients. ClinicalTrials.gov identifier: NCT00402519.Patient compliance was excellent in both arms. Both WBI and APBI were well tolerated with moderate early side-effects. No grade 4 toxicity had been observed. Grade 3 side effects were exclusively seen for early skin toxicity (radiation dermatitis) with 7% vs. 0.2% (p<0.0001), and breast infection with 0% vs. 0.2% (p=n.s.) for patients treated with WBI and APBI. The incidence of grades 1-2 early side effects for WBI and APBI was 86% vs. 21% (p<0.0001) for skin toxicity, 2% vs. 20% (p<0.0001) for mild hematoma, and 2% vs. 5% (p=0.01) for mild breast infection rates, respectively. No differences had been found regarding grades 1-2 early breast pain (26% vs. 29%, p=0.23).APBI with interstitial multicatheter brachytherapy was tolerated very well and dramatically reduced early skin toxicity in comparison to standard WBI.

Authors with CRIS profile

Involved external institutions

Clemenshospital Germany (DE) Universitätsklinikum Leipzig Germany (DE) Vienna General Hospital / Allgemeines Krankenhaus der Stadt Wien (AKH) Austria (AT) Universitätsmedizin Rostock Germany (DE) Országos Onkológiai Intézet / National Institute of Oncology Hungary (HU) Maria Skłodowska-Curie Institute of Oncology / Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie Poland (PL) Valencia Oncology Institute Foundation / Fundación Instituto Valenciano de Oncología / Fundació Institut Valencià d’Oncologia (IVO) Spain (ES) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Catalan Institute of Oncology / Institut Català d'Oncologia (ICO) Spain (ES) Masaryk Memorial Cancer Institute (MMCI) / Masarykův onkologický ústav (MOÚ) Czech Republic (CZ) Krankenhaus Barmherzige Brüder Germany (DE) Inselspital, Universitätsspital Bern Switzerland (CH) Universitätsklinikum Würzburg Germany (DE) Universitätsklinikum Jena Germany (DE)

How to cite

APA:

Ott, O.J., Strnad, V., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T.,... Polgar, C. (2016). GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance. Radiotherapy and Oncology, 120(1), 119-23. https://doi.org/10.1016/j.radonc.2016.06.019

MLA:

Ott, Oliver J., et al. "GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance." Radiotherapy and Oncology 120.1 (2016): 119-23.

BibTeX: Download